Latest Period
Q1 2026
Security Snapshot
Beam Therapeutics Inc. - Common Stock (BEAM) Institutional Ownership
CUSIP: 07373V105
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
247
Shares (Excl. Options)
108,246,388
Price
$23.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- BEAM on Nasdaq
- Shares outstanding
- 102,041,335
- Price per share
- $29.38
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 108,246,388
- Total reported value
- $2,578,184,925
- % of total 13F portfolios
- 0%
- Share change
- +1,910,562
- Value change
- +$33,081,234
- Number of holders
- 247
- Price from insider filings
- $29.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- BEAM - Beam Therapeutics Inc. - Common Stock is tracked under CUSIP 07373V105.
- 247 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 243 to 247 between Q4 2025 and Q1 2026.
- Reported value moved from $2,962,655,717 to $2,578,184,925.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 247 institutions filings for Q1 2026.
Security key
07373V105
Latest holder period
Q1 2026
13F holders
247
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
BEAM full holder history
Beam Therapeutics Inc. SEC filings
Beam Therapeutics Inc. company facts
Beam Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 07373V105:
Significant Owners of Beam Therapeutics Inc. - Common Stock (BEAM) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 13% | -7.1% | $353,440,240 | -$28,167,623 | 12,750,369 | -7.4% | FMR LLC | 31 Dec 2025 |
| ARK Investment Management LLC | 12% | +19% | $345,590,479 | +$57,021,481 | 12,467,189 | +20% | ARK Investment Management LLC | 31 Dec 2025 |
| Farallon Capital Partners, L.P. | 10% | 0% | $281,132,248 | +$4,681,243 | 10,141,856 | +1.7% | Dapice Joshua J. | 31 Dec 2025 |
| BlackRock, Inc. | 7.5% | $147,823,620 | 7,499,930 | BlackRock, Inc. | 31 Mar 2025 | |||
| STATE STREET CORP | 5.2% | $144,934,824 | 5,228,529 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $122,068,579 | 5,122,475 | Vanguard Capital Management | 31 Mar 2026 | |||
| ARCH Venture Fund IX, L.P. | 4.6% | -17% | $90,680,723 | 4,600,747 | 0% | Robert Nelsen | 31 Mar 2025 |
As of 31 Mar 2026, 247 institutional investors reported holding 108,246,388 shares of Beam Therapeutics Inc. - Common Stock (BEAM). This represents 106% of the company’s total 102,041,335 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Beam Therapeutics Inc. - Common Stock (BEAM) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 12% | 12,452,199 | +4.6% | 0.02% | $296,735,900 |
| ARK Investment Management LLC | 12% | 12,133,433 | -2.7% | 2.2% | $289,139,697 |
| FARALLON CAPITAL MANAGEMENT LLC | 9.9% | 10,134,696 | +0.71% | 1.6% | $241,509,806 |
| BlackRock, Inc. | 8.3% | 8,487,569 | +0.44% | 0% | $202,258,769 |
| STATE STREET CORP | 5.6% | 5,699,265 | +9% | 0% | $135,813,485 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | 4,570,797 | 0% | 0.01% | $108,922,093 |
| ARCH Venture Management, LLC | 4.4% | 4,540,132 | 0% | 16% | $108,191,346 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 4,377,374 | 0% | 0% | $104,312,822 |
| Amova Asset Management Americas, Inc. | 3.7% | 3,825,585 | -13% | 1.3% | $91,163,691 |
| Sumitomo Mitsui Trust Group, Inc. | 3.7% | 3,825,585 | -13% | 0.06% | $91,163,691 |
| Kynam Capital Management, LP | 3.6% | 3,682,185 | +51% | 5.6% | $87,746,469 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 2,713,230 | -0.62% | 0.01% | $64,658,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,418,592 | +2.8% | 0% | $57,647,252 |
| DIMENSIONAL FUND ADVISORS LP | 2.1% | 2,154,575 | +11% | 0.01% | $51,326,975 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.6% | 1,653,714 | -3.4% | 0.01% | $39,408,002 |
| ADAR1 Capital Management, LLC | 1.4% | 1,446,375 | 2.1% | $34,467,116 | |
| Casdin Capital, LLC | 1.3% | 1,350,000 | -16% | 2.4% | $32,170,500 |
| Redmile Group, LLC | 1.2% | 1,237,659 | -3.7% | 2% | $29,493,414 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 1,210,853 | +8.1% | 0.02% | $28,854,627 |
| Qube Research & Technologies Ltd | 1.1% | 1,084,768 | +171% | 0.04% | $25,850,021 |
| GOLDMAN SACHS GROUP INC | 0.99% | 1,005,743 | +92% | 0% | $23,966,855 |
| UBS Group AG | 0.81% | 826,061 | -15% | 0% | $19,685,034 |
| NORTHERN TRUST CORP | 0.81% | 825,580 | +2.1% | 0% | $19,673,572 |
| Deep Track Capital, LP | 0.8% | 820,765 | 0.4% | $19,558,830 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.79% | 808,436 | -3.2% | 0% | $19,265,030 |
Institutional Holders of Beam Therapeutics Inc. - Common Stock (BEAM) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 108,246,388 | $2,578,184,925 | +$33,081,234 | $23.83 | 247 |
| 2025 Q4 | 106,860,472 | $2,962,655,717 | +$15,891,836 | $27.72 | 243 |
| 2025 Q3 | 106,531,653 | $2,585,329,209 | -$9,441,913 | $24.27 | 214 |
| 2025 Q2 | 108,325,993 | $1,842,599,951 | +$102,159,924 | $17.01 | 213 |
| 2025 Q1 | 101,329,623 | $1,984,124,636 | +$387,248,348 | $19.53 | 234 |
| 2024 Q4 | 81,429,029 | $2,019,888,804 | +$52,922,730 | $24.80 | 228 |
| 2024 Q3 | 78,929,001 | $1,933,839,851 | +$32,128,779 | $24.50 | 217 |
| 2024 Q2 | 77,540,507 | $1,816,892,862 | +$138,460,483 | $23.43 | 210 |
| 2024 Q1 | 70,332,894 | $2,323,064,829 | +$51,308,447 | $33.04 | 217 |
| 2023 Q4 | 68,925,790 | $1,876,215,663 | +$46,457,918 | $27.22 | 183 |
| 2023 Q3 | 67,439,160 | $1,621,864,483 | +$72,305,572 | $24.05 | 190 |
| 2023 Q2 | 64,198,552 | $2,049,551,170 | +$123,991,732 | $31.93 | 191 |
| 2023 Q1 | 60,372,846 | $1,848,161,788 | +$134,989,244 | $30.62 | 205 |
| 2022 Q4 | 55,910,182 | $2,186,652,051 | +$42,258,811 | $39.11 | 205 |
| 2022 Q3 | 54,633,598 | $2,601,918,929 | -$6,231,369 | $47.64 | 214 |
| 2022 Q2 | 54,764,598 | $2,088,902,541 | +$192,782,034 | $38.71 | 191 |
| 2022 Q1 | 49,225,196 | $2,820,671,022 | +$201,996,007 | $57.30 | 230 |
| 2021 Q4 | 45,547,893 | $3,629,719,477 | -$39,454,291 | $79.69 | 224 |
| 2021 Q3 | 45,176,306 | $3,933,867,577 | -$43,842,015 | $87.01 | 223 |
| 2021 Q2 | 45,484,033 | $5,854,372,685 | +$342,578,385 | $128.71 | 223 |
| 2021 Q1 | 43,012,900 | $3,436,702,468 | +$478,571,473 | $80.04 | 203 |
| 2020 Q4 | 36,917,618 | $3,014,269,128 | +$632,622,766 | $81.64 | 152 |
| 2020 Q3 | 29,525,955 | $726,945,347 | +$39,624,702 | $24.62 | 84 |
| 2020 Q2 | 27,707,853 | $775,554,484 | +$34,103,632 | $28.00 | 70 |
| 2020 Q1 | 26,888,544 | $483,990,454 | +$483,990,450 | $18.00 | 60 |